CG Oncology, Inc. reports developments as a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec for bladder cancer. Its updates center on non-muscle invasive bladder cancer, including high-risk BCG-unresponsive, BCG-exposed and intermediate-risk disease settings, and describe clinical studies such as PIVOT-006, BOND-003 and CORE-008.
Recurring company news also covers financial results, FDA-related regulatory planning, clinical data presentations, manufacturing and BLA preparation, investor conference participation and research initiatives tied to NMIBC. The company's disclosures connect its operating cash position and development spending to the advancement of its bladder-sparing immunotherapy program.
CG Oncology reported their financial results for the first quarter of 2024, showcasing a 75.2% Complete Response Rate for their Cretostimogene Monotherapy in patients with High-Risk Non-Muscle Invasive Bladder Cancer. The company also dosed the first patient in a Phase 3 trial and presented final results from a Phase 2 trial of Cretostimogene in combination with Pembrolizumab. In addition, they completed an oversubscribed $437 million IPO and expect their cash runway to last until 2027.
CG Oncology, Inc. announced positive Phase 3 BOND-003 study results for cretostimogene monotherapy in treating high-risk, BCG-unresponsive Non-Muscle Invasive Bladder Cancer. The study showed a 75.2% complete response rate with durable responses over 12 months. No Grade 3 or higher treatment-related adverse events were reported. Cretostimogene has the potential to be a preferred therapy over surgical options in this patient population.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.